Ocrelizumab

Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody.[3] It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug.[4] Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.[4] It was approved by the U.S. Food and Drug Administration (FDA) in March 2017,[5] and th... [wikipedia]